Peptide
IGF-1 DES
SaveA truncated form of IGF-1 lacking the first 3 amino acids (des(1-3) IGF-1), resulting in reduced binding to IGF-binding proteins and increased bioactivity.
Quick verdict
More potent than native IGF-1 at the receptor level due to reduced protein binding. No approved clinical use; carries amplified risks of IGF-1 including hypoglycemia.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Well-characterized biochemically. No clinical trials for any indication. Used in cell-culture research and illicitly in bodybuilding.
Benefits
- Higher receptor-level potency than native IGF-1
- Reduced sequestration by binding proteins in vitro
Dosage notes
No validated human dosing. Research use only.
Side effects
- Severe hypoglycemia
- Theoretical increased cancer risk
- Injection-site reactions
Who should be cautious
Higher potency means amplified risks. Severe hypoglycemia danger. No quality-controlled products available.
What this page cannot tell you
Entirely preclinical from a therapeutic perspective. Potency increase does not mean improved safety profile.
Leaderboard scores
- Muscle40
Write a review
Sign in to write a review.